The invention relates to a continuous method for producing a tenside, containing a compound of the formula (1), wherein R.sup.2 is a fatty acid alkyl residue and R.sup.1 is a linear or branched C.sub.1 to C.sub.12 hydrocarbon residue, and x is in the range from 1 to 15 by conversion of fatty acid alkyl esters or fatty acid triglycerides having an N-n-alkylized polyhydroxy compound in the presence of an alkali catalyst or a catalyst selected from hydroxides or alcoholates of the 2nd and 4th secondary group of the periodic system at a temperature in the range from 40 to 300 C. ##STR00001##

The invention relates to a continuous method for producing a tenside, containing a compound of the formula (1), wherein R.sup.2 is a fatty acid alkyl residue and R.sup.1 is a linear or branched C.sub.1 to C.sub.12 hydrocarbon residue, and x is in the range from 1 to 15 by conversion of fatty acid alkyl esters or fatty acid triglycerides having an N-n-alkylized polyhydroxy compound in the presence of an alkali catalyst or a catalyst selected from hydroxides or alcoholates of the 2nd and 4th secondary group of the periodic system at a temperature in the range from 40 to 300 C. ##STR00001##

The present invention provides an ionic liquid composition containing an ionic liquid and water. The ionic liquid composition does not contain an enzyme capable of hydrolyzing cellulose. The ionic liquid is represented by the following chemical formula (I): [(CH.sub.3).sub.3N(CH.sub.2).sub.2OH].sup.+[NH.sub.2-L-CHNH.sub.2COO].sup. (I); where L is absent or a linker. A molar ratio of [(CH.sub.3).sub.3N(CH.sub.2).sub.2OH].sup.+ to [NH.sub.2-L-CHNH.sub.2COO].sup. is not less than 0.87 and not more than 1.14. A weight ratio of the water to the ionic liquid composition is not more than 7.3%. The present invention provides an ionic liquid composition capable of dissolving cellulose without a cellulose-degrading enzyme, namely, an enzyme capable of hydrolyzing cellulose.

The present invention relates to a process for synthesis of Eliglustat and intermediate compounds thereof. In particular, the present invention relates to a process for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and relates to the intermediate compounds in the process and a process for preparation of the intermediate compounds.

The present invention relates to a process for synthesis of Eliglustat and intermediate compounds thereof. In particular, the present invention relates to a process for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and relates to the intermediate compounds in the process and a process for preparation of the intermediate compounds.

The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.

The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.

The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

The inventive concepts disclosed and/or claimed herein relate generally to catalysts and, more particularly, but not by way of limitation, to a heterogeneous, metal-free hydrogenation catalyst containing frustrated Lewis pairs. In one non-limiting embodiment, the heterogeneous, metal-free catalyst comprises hexagonal boron nitride (h-BN) having frustrated Lewis pairs therein.